Dr. Lal Pathlabs Ltd. (LALPATHLAB) Share Price Hits Fresh 52-Week High

Dr. Lal Pathlabs Ltd. Share Price hits a fresh 52-week high at Rs 1910 with a market cap of Rs 30,279.57 Cr.

Dr. Lal Pathlabs Ltd. Share Price has reached a fresh 52-week high of Rs 1910 today, marking a significant milestone for the company. The current price stands at Rs 1887.6, reflecting a modest increase of 0.29% from the previous close of Rs 1882.15. The company's market capitalisation is Rs 30,279.57 Cr, underscoring its substantial presence in the healthcare sector. This achievement highlights the stock's upward momentum, drawing attention from investors and analysts alike. The data confirms the price event, although no specific company catalyst is identified.

Dr. Lal Pathlabs Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,887.6
Previous Close	Rs 1,882.15
Today's Change	+Rs 5.45 (+0.29%)
Day Open	Rs 1,893.4
Fresh 52-Week High	Rs 1,910
Day Low	Rs 1,870
Current Volume	4,217
Turnover	Rs 0.8 crore
Market Capitalisation	Rs 30,279.57 crore

Dr. Lal Pathlabs Ltd. (LALPATHLAB) traded at Rs 1,887.6. versus the previous close of Rs 1,882.15, a rise of 0.29%. The stock opened at Rs 1,893.4, reached Rs 1,910, touched Rs 1,870. Reported volume was 4,217.

Today's trading session saw Dr. Lal Pathlabs Ltd. opening at Rs 1893.4, reaching a high of Rs 1910, and a low of Rs 1870. The stock's turnover was Rs 0.8 Cr, with a volume of 4217 shares traded. The fresh 52-week high indicates a breakout, with the stock surpassing its previous high. The modest day change of 0.29% suggests steady investor interest, while the volume indicates moderate participation. This price action sets the stage for further analysis of the company's fundamentals and sector positioning.

Dr. Lal Pathlabs Ltd. (LALPATHLAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 30,279.57 crore
P/E Ratio	30.28x
P/B Ratio	0.44x
ROE	-2.89%
ROCE	-0.26%

Dr. Lal Pathlabs Ltd. was valued at a P/E ratio of 30.28x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	30.28x
Benchmark Median P/E	21.7x
Benchmark Average P/E	68.16x
Benchmark P/E Range	0x to 3,385.56x
Company P/B Ratio	0.44x
Benchmark Median P/B	1.9x
Company ROE	-2.89%
Benchmark Median ROE	10.73%
Company ROCE	-0.26%
Benchmark Median ROCE	13.2%
Company Market Capitalisation	Rs 30,279.57 crore
Benchmark Median Market Cap	Rs 138.42 crore

Dr. Lal Pathlabs Ltd. (LALPATHLAB) is classified under sector: Healthcare.

Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a P/E ratio of 30.28x, which is above the benchmark median of 21.7x, a difference of +39.54%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a ROE of -2.89%, which is below the benchmark median of 10.73%, a difference of -126.93%. Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,856.59	30.28	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,686.76	40.11	8.17	28.21	26.35
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,432.22	34.7	7.02	-2.6	16.92
Sai Parenteral's Ltd.	SAIPARENT	2,415.06	171.06	3.16	13.9	12.97
Beta Drugs Ltd.	BETA	2,338.9	59.68	9.44	18.65	22.17

Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a P/E ratio of 30.28x compared with the displayed peer median of 40.11x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a market capitalisation of Rs 30,279.57 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Dr. Lal Pathlabs Ltd.

• Fresh 52-week high at Rs 1910, indicating strong price momentum.
• Market cap of Rs 30,279.57 Cr, showcasing its industry leadership.
• Attractive P/E and P/B ratios compared to sector medians.
• Negative ROE and ROCE, suggesting profitability challenges.
• Strong sector presence with 198 healthcare companies.

About Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. is a prominent player in the healthcare sector, providing diagnostic and related healthcare tests. The company operates a network of laboratories and patient service centers across India, offering a wide range of tests and services. Its comprehensive diagnostic services cater to a broad spectrum of healthcare needs, positioning it as a leader in the industry. With a focus on quality and innovation, Dr. Lal Pathlabs Ltd. continues to expand its reach and enhance its service offerings.

Track Dr. Lal Pathlabs Ltd. Share Price on Univest

Use Dr. Lal Pathlabs Ltd. (LALPATHLAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track Dr. Lal Pathlabs Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay updated with the latest market trends and analysis to make informed investment decisions.

Frequently Asked Questions

What is the current share price of Dr. Lal Pathlabs Ltd.?

Ans. The current share price of Dr. Lal Pathlabs Ltd. is Rs 1887.6, reflecting a 0.29% increase from the previous close of Rs 1882.15. The stock moved 0.29% during the session.

What is Dr. Lal Pathlabs Ltd.'s market capitalisation?

Ans. Dr. Lal Pathlabs Ltd.'s market capitalisation is Rs 30,279.57 Cr, indicating its substantial presence in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.28x.

How does Dr. Lal Pathlabs Ltd.'s P/E ratio compare to the sector?

Ans. Dr. Lal Pathlabs Ltd.'s P/E ratio of 30.28 is above the sector median of 21.7 but below the average of 68.16, suggesting a balanced valuation. The company trades at a P/E ratio of 30.28x.

What is the significance of the 52-week high for Dr. Lal Pathlabs Ltd.?

Ans. The 52-week high of Rs 1910 indicates strong price momentum and investor interest in Dr. Lal Pathlabs Ltd., marking a significant milestone. The stock moved 0.29% during the session. The intraday range extended from Rs 1,870 to Rs 1,910.

How does Dr. Lal Pathlabs Ltd.'s ROE compare to its peers?

Ans. Dr. Lal Pathlabs Ltd.'s ROE of -2.89 is lower than its peers, highlighting challenges in profitability compared to competitors. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.73%.

Who are Dr. Lal Pathlabs Ltd.'s main competitors?

Ans. Dr. Lal Pathlabs Ltd.'s main competitors include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Dr Agarwals Eye Hospital Ltd. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Dr Agarwals Eye Hospital Ltd.

What is the sector context for Dr. Lal Pathlabs Ltd.?

Ans. Dr. Lal Pathlabs Ltd. operates in the healthcare sector, competing with 198 companies, with a sector P/E median of 21.7 and ROE median of 10.73. The stock belongs to the Healthcare sector.

What is Dr. Lal Pathlabs Ltd.'s P/B ratio?

Ans. Dr. Lal Pathlabs Ltd.'s P/B ratio is 0.44, significantly lower than the sector median of 1.9, indicating potential undervaluation. The company trades at a P/E ratio of 30.28x. Its P/B ratio is 0.44x.

How does Dr. Lal Pathlabs Ltd.'s market cap compare to its peers?

Ans. Dr. Lal Pathlabs Ltd.'s market cap of Rs 30,279.57 Cr is significantly higher than its peers, showcasing its industry leadership. The company operates in the Healthcare sector. Its P/E ratio is 30.28x.